Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of “Hold” from Analysts

Moderna, Inc. (NASDAQ:MRNA) has been assigned a consensus recommendation of “Hold” from the twenty-three research firms that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $53.95.

MRNA has been the subject of several recent research reports. Evercore ISI decreased their price objective on Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a research note on Friday, May 2nd. Royal Bank of Canada decreased their price objective on Moderna from $32.00 to $28.00 and set a “sector perform” rating for the company in a research note on Friday, May 2nd. UBS Group decreased their price objective on Moderna from $78.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. JPMorgan Chase & Co. decreased their price objective on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Friday, March 21st. Finally, Barclays decreased their price objective on Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a research note on Friday, May 2nd.

Moderna Stock Performance

NASDAQ MRNA opened at $24.86 on Monday. The firm has a 50 day simple moving average of $27.87 and a 200-day simple moving average of $35.44. Moderna has a one year low of $23.15 and a one year high of $170.47. The firm has a market cap of $9.61 billion, a price-to-earnings ratio of -2.68 and a beta of 1.99.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. During the same quarter last year, the firm posted ($3.07) earnings per share. The business’s revenue for the quarter was down 35.3% compared to the same quarter last year. Equities analysts predict that Moderna will post -9.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Allworth Financial LP increased its holdings in shares of Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after purchasing an additional 281 shares during the period. Howard Capital Management Inc. increased its holdings in shares of Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock valued at $416,000 after purchasing an additional 297 shares during the period. Itau Unibanco Holding S.A. increased its holdings in shares of Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock valued at $42,000 after purchasing an additional 343 shares during the period. Commonwealth Equity Services LLC increased its holdings in shares of Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock valued at $3,099,000 after purchasing an additional 345 shares during the period. Finally, Larson Financial Group LLC increased its holdings in shares of Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company’s stock valued at $53,000 after purchasing an additional 356 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.